Clinical Trial Update: Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI [EARLY_Phase 1]

View source ↗

Summary

Update on an early-phase trial evaluating the safety and immune response of MAGE-A3 ASCI in patients with resected stage IIB-IV melanoma; the study is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• MAGE-A3 Antigen-Specific Cancer Immunotherapy (ASCI) (MAGE-A3)

Snippet

Sponsor: Craig L Slingluff, Jr | Conditions: Melanoma | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2016-04-04